PPCBPropanc Biopharma, Inc.

About Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma, Inc. (PPCB) is a Biotechnology company headquartered in Camberwell, VA, Australia whose shares trade over-the-counter on the Pink tier.

Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers. The Company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer.

Products and services

Propanc Biopharma is a development stage healthcare company focused on developing new cancer treatments for patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. The Company has developed a novel formulation of anti-cancer compounds, which exerts a number of effects designed to control or prevent tumors from recurring and spreading through the body. Propanc Biopharma’s lead product candidate, PRP, consists of pancreatic proenzymes which are the inactive precursors of enzymes. The Company has conducted successful pre-clinical studies and hopes to initiate a First-In-Human study for the treatment of solid tumors in advanced cancer patients. The Company intends to advance the development of PRP through early-stage clinical development and then seek a licensee for further development. The goal is to develop PRP for the treatment of early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening. Propanc Biopharma coordinates research and development activities by partnering with research and manufacturing organizations globally to discover and grow the Company’s intellectual property portfolio in order to achieve product approval in major pharmaceutical markets including the U.S., Europe, the UK, Australia and Japan. The Company also hopes to acquire new companies or intellectual property with novel products or services that complements the Company’s future goals.

PPCB key facts

Ticker symbol

PPCB

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Camberwell, VA, Australia

Country of incorporation

US

Employees

2

Estimated market cap

$120.8K (as of Apr 10, 2025)

Shares outstanding

19,326

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

6/30

Propanc Biopharma, Inc. leadership

• James Nathanielsz — CEO, CFO
• Julian Kenyon — Chief Scientific Officer

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with P